narcolepsy type 2
Selected indexed studies
- Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1. (N Engl J Med, 2025) [PMID:40367374]
- Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1. (N Engl J Med, 2023) [PMID:37494485]
- Narcolepsy type 2: phenotype is fundamental. (Sleep, 2024) [PMID:38452192]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1. (2025) pubmed
- Narcolepsy and Idiopathic Hypersomnia. (2023) pubmed
- REM sleep in narcolepsy. (2024) pubmed
- Effects of Oveporexton, an Orexin Receptor 2-Selective Agonist, on Cognition in Narcolepsy Type 1: A Secondary Analysis of a Randomized Clinical Trial. (2026) pubmed
- Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1. (2023) pubmed
- Narcolepsy. (2022) pubmed
- Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. (2019) pubmed
- Narcolepsies, update in 2023. (2023) pubmed
- Narcolepsy type 2: phenotype is fundamental. (2024) pubmed
- Narcolepsy type 2: A rare, yet existing entity. (2021) pubmed